NOVO — November 2023
-
MF det tror jeg ikke. Det ligner lidt der skal en del nye forsøg til for at kunne fortage en sådan konklusion. Herunder H2H med andre stoffer
-
A key question about the initial results, though, remained not fully answered: Is the heart benefit from Wegovy attributable to how much weight people lose while using the medicine? Or is it because Wegovy has other effects as well?
-
“It remains unclear to what degree the trial findings were dependent on weight loss, concomitant reductions in risk factors, or other salutary mechanisms of GLP-1 receptor agonism,”
-
“I think most of us believe that some of this is weight loss, but I think that that oversimplifies a very complex molecule, a complex receptor on multiple tissues, and I don’t think it’s as a simple as that,” he said. “That’s part of the reason why I don’t think weight loss itself is the surrogate; we have to look at the mechanism of the weight loss.”
-
He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come.
“This is the population who needs the medicine the most,” said Lopez-Jimenez, who had no role in the study.
In the U.S., there are about 6.6 million people like those tested in the study, experts said.
-
flere er allerede ude at sige de 6,6 mio amerikanere der er i samme patientgruppe som dem der var med i forsøget. At de bør få wegovy
-
6,6 mio er en oms på godt 400 mia med den nuværende netto pris i US........
-
Det kan godt være novo i går meldte ud om 42 mia investering i ny giga fabrik i DK. Men der burde komme en lignede eller endda endnu støre investering i US.
-
Fra mit indlæg på Linkedin:
Claus JohansenView Claus Johansen’s profile • 1st Founder and CEO GlobalHealthInvest
6m
"Ja det er vildt flotte data. Og folk klappede meget efter præsentationen her i Philadelphia. Med ingen “nasty”
overraskelser, så tegner det godt for Novo"! -
MF: LLY har et ligende studie. Det forventes dog først at afrapportere i 2027. Så Novo er alt andet lige alene i 3-4 år med den indlægsseddel
-
Mange flere ekspert kommentar her https://www.medscape.com/viewarticle/998373?form=fpf
-
Spændende hvad det betyder for kursen mandag morgen.
-
Novo Nordisks vægttabsmedicin imponerer: Bremser udvikling af diabetes https://borsen.dk/nyheder/virksomheder/novo-nordisks-vaegttabsmedicin-har-flere-sidegevinster?b_source=borsen&b_medium=row_1&b_campaign=list_6
-
Fra Børsen "Hvis Select-data viser en væsentlig virkning ved at forhindre udvikling af diabetes, kan det resultere i en meget stærk produktlabel for Wegovy,” vurderede Michael Novod, medicinalanalytiker i Nordea i en kommentar forud for AHA-konferencen."
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind